Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

Stephen CaldwellMark L HartmanEric J LawitzRaj VuppalanchiJérôme BoursierElisabetta BugianesiMasato YonedaCynthia BehlingOscar W CummingsYuanyuan TangBram BrouwersDeborah A RobinsAmir NikooieMathijs C BunckAxel HauptArun J Sanyalnull null

Published in: The New England journal of medicine (2024)

In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).

Keyphrases

liver fibrosis
oxidative stress
high intensity
early onset
single molecule
replacement therapy
double blind
open label